% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Schttke:282733,
      author       = {V. Schüttke and C. Kusiek and S. Fuessel$^*$ and C. Thomas
                      and B. T. Buerk and K. Erdmann$^*$},
      title        = {{E}arly kinetics of {C}-reactive protein as prognosticator
                      for survival in a real-world cohort of patients with
                      metastatic renal cell cancer under first-line therapy with
                      immune checkpoint inhibitors.},
      journal      = {Clinical and translational oncology},
      volume       = {26},
      number       = {5},
      issn         = {1699-048X},
      address      = {Mailand},
      publisher    = {Springer Milan},
      reportid     = {DKFZ-2023-01859},
      pages        = {1117-1128},
      year         = {2024},
      note         = {2024 May;26(5):1117-1128},
      abstract     = {This study investigated the prognostic potential of
                      baseline C-reactive protein (CRP) levels and early CRP
                      kinetics in a real-world cohort of patients with metastatic
                      renal cell carcinoma (mRCC) under first-line (1L) therapy
                      with immune checkpoint inhibitors (CPI).Analyses were
                      performed retrospectively in a cohort of 61 mRCC patients
                      under CPI-based 1L therapy. Patients were stratified based
                      on baseline CRP (< 10 vs ≥ 10 mg/l) and CRP change within
                      the initial three months of CPI therapy (normal: baseline <
                      10 mg/l, normalized: baseline ≥ 10 mg/l and nadir < 10
                      mg/l, non-normalized: baseline and nadir ≥ 10 mg/l).
                      Finally, the association of baseline CRP and CRP change with
                      progression-free (PFS) and overall survival (OS) was
                      evaluated.Baseline CRP was not significantly associated with
                      both PFS (p = 0.666) and OS (p = 0.143). Following
                      stratification according to early CRP kinetics, 23, 25 and
                      13 patients exhibited normal, normalized and non-normalized
                      CRP levels, respectively. Patients with normal and
                      normalized CRP had a markedly prolonged PFS (p = 0.091) and
                      OS (p = 0.008) compared to patients with non-normalized CRP.
                      Consequently, significantly better PFS (p = 0.031) and OS (p
                      = 0.002) were observed for the combined normal-normalized
                      group. In multivariate analysis including ECOG and IMDC
                      risk, normalized CRP kinetics alone or in combination with
                      the normal group was identified as significant independent
                      risk factor for OS, whereas a statistical trend was observed
                      for PFS.The present study emphasizes the prognostic
                      potential of early CRP kinetics in CPI-treated mRCC. As a
                      standard laboratory parameter, CRP can be easily implemented
                      into clinical routine to facilitate therapy monitoring.},
      keywords     = {Biomarker (Other) / CRP kinetics (Other) / Immunotherapy
                      (Other) / Metastatic renal cell carcinoma (Other) /
                      Prognosis (Other) / Tyrosine kinase inhibitors (Other)},
      cin          = {DD01},
      ddc          = {610},
      cid          = {I:(DE-He78)DD01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37695463},
      doi          = {10.1007/s12094-023-03317-z},
      url          = {https://inrepo02.dkfz.de/record/282733},
}